Preclinical development of CD38-targeted [89Zr]Zr-DFO-daratumumab for imaging multiple myeloma.
Ghai A et al. J Nucl Med. 2017 Oct 12. pii: jnumed.117.196063. doi: 10.2967/jnumed.117.196063. [Epub ahead of print].
Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma.
Kumar S et al. Blood. 2017 Oct 10. pii: blood-2017-06-788786. doi: 10.1182/blood-2017-06-788786. [Epub ahead of print].
Phase-I randomized trial of doxorubicin hydrochloride liposome injection versus Caelyx® in multiple myeloma.
Bhowmik S et al. Leuk Lymphoma. 2017 Oct 10:1-4. doi: 10.1080/10428194.2017.1382692. [Epub ahead of print].
Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients.
Avet-Loiseau H et al. Blood. 2017 Oct 20. pii: blood-2017-06-791228. doi: 10.1182/blood-2017-06-791228. [Epub ahead of print].
Denosumab for the treatment of bone disease in solid tumors and multiple myeloma.
Yee AJ et al. Future Oncol. 2017 Oct 20. doi: 10.2217/fon-2017-0403. [Epub ahead of print].
Emerging small molecule approaches to enhance the antimyeloma benefit of proteasome inhibitors.
Driscoll JJ et al. Cancer Metastasis Rev. 2017 Oct 19. doi: 10.1007/s10555-017-9698-5. [Epub ahead of print].